The fate of chemoresistance in triple negative breast cancer (TNBC)
2015 · BBA Clinical · 371 citations
https://doi.org/10.1016/j.bbacli.2015.03.003
M
Matthew Ho
Northwell Health(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
114
Papers
2.3K
Citations
21
h-index
29
i10-index
Matthew Ho is an academic researcher from Northwell Health. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Protein Degradation and Inhibitors & Ubiquitin and proteasome pathways. The author has an h-index of 21, co-authored 97 publications.
ORCID: 0000-0001-7937-1557Papers by this author
worksProtein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells
2017 · Oncogenesis · 102 citations
https://doi.org/10.1038/oncsis.2017.82
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling
2019 · Leukemia · 74 citations
https://doi.org/10.1038/s41375-019-0493-x
An atlas of the bone marrow bone proteome in patients with dysproteinemias
2023 · Blood Cancer Journal · 7 citations
https://doi.org/10.1038/s41408-023-00840-8
Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
2024 · British Journal of Urology · 2 citations
https://doi.org/10.1111/bju.16618
MOESM1 of Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era
2017 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.c.3827578_d1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat